A multicenter clinical study of transcriptome high-throughput sequencing and targeted therapy in children with refractory or relapsed acute myeloid leukemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036427

Enrollment

Unknown

Registered

2020-08-23

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory or relapsed acute myeloid leukemia

Interventions

sigle arm:Decitabine+CLAG

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Relapsed or refractory AML included granulocytic sarcoma and MDS-RAEBT; (2) ages younger than 18 years old; (3) Obtain the consent of the guardian or and patient, and sign on the informed consent form; (4) The estimated survival time was more than 3 months.

Exclusion criteria

Exclusion criteria: (1) Juvenile myelomonocytic leukemia (JMML); (2) AML secondary to Fanconi anemia (FA); (3) AML secondary to Down syndrome; (4) AML secondary to any other congenital disease; (5) only temporary chemotherapy, radiotherapy or immunotherapy, but not systematic treatment according to the treatment plan; (6) Coexisting diseases or mental diseases with any significant abnormality affect the life safety and compliance of patients; (7) Patients with poor nutritional status, severe infection, cardiac insufficiency, and unable to tolerate chemotherapy.

Design outcomes

Primary

Measure	Time frame
overall survive;remission rate;	—

Secondary

Measure	Time frame
MRD;mutate gene;fusion gene;	—

Countries

China

Contacts

Public ContactNa Zhang

Shanghai Children's Hospital

abczhangna@hotmail.com+86 18101887300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026